YOLT-203 for type 1 primary hyperoxaluria (PH1)
Part of Genetic & congenital, Kidney & urinary clinical trials.
This trial tests an experimental drug called YOLT-203 for people with type 1 primary hyperoxaluria (PH1), a rare condition that causes high oxalate levels and can damage the kidneys. It aims to see if YOLT-203 can safely help manage the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 2 years old.
- You have been diagnosed with primary hyperoxaluria type 1 (PH1) due to an AGXT gene mutation.
- Your kidney function (eGFR) is 30 or higher—a measure of how well your kidneys are working.
- You have high oxalate levels in your urine, measured either over 24 hours or in a single sample.
- If you take vitamin B6, your dose has been stable for at least 90 days before starting the study and you are willing to keep it the same during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new treatment for primary hyperoxaluria type 1, a rare condition that causes too much oxalate in the body, which can lead to kidney stones and kidney damage. The treatment is given as an injection, and the study will see if it is safe and how the body responds.
This trial tests a new intravenous medicine called YOLT-201 for people with a heart condition caused by buildup of a protein called transthyretin (ATTR-CM). The goal is to see if it can slow or improve the disease.
This trial tests a new gene therapy called YOLT-101 for people with familial hypercholesterolemia, a genetic condition that causes very high cholesterol. The treatment aims to lower cholesterol levels and reduce heart risks.
This study tests a new drug called YOLT-203 for people with primary hyperoxaluria type 1 (PH1), a rare genetic condition where the body produces too much oxalate, which can damage the kidneys. The trial aims to see if this drug can help reduce oxalate levels and prevent kidney damage.
This trial tests a new treatment called ABO-101 for people with primary hyperoxaluria type 1, a rare disease that causes high oxalate levels in urine. The study aims to see if ABO-101 can lower oxalate and protect kidney function.
This Phase 2 study tests a medicine called DCR-PHXC to lower body oxalate levels in people with PH1 who have advanced kidney failure. By lowering oxalate, the treatment may reduce harm from oxalate buildup and help researchers understand safety and effectiveness.
Hear when a new Type 1 Primary Hyperoxaluria trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.